🇺🇸 FDA
Pipeline program

Lumicitabine

CR108367

Phase 2 small_molecule terminated

Quick answer

Lumicitabine for Respiratory Syncytial Viruses is a Phase 2 program (small_molecule) at Janssen Cilag International NV with 1 ClinicalTrials.gov record(s).

Program details

Company
Janssen Cilag International NV
Indication
Respiratory Syncytial Viruses
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials